Recall of three metformin products found to contain NDMA
Healthcare professional
Therapeutic Products
4 December 2019
This article has been migrated from an earlier version of the site and may display formatting inconsistencies.
The Health Sciences Authority (HSA) would like to inform healthcare professionals about the recall of three metformin products which have been detected to contain trace amounts of N-nitrosodimethylamine (NDMA) beyond the internationally acceptable level. HSA has tested all the metformin products in the Singapore market, and found that besides these three products, none of the other 43 metformin products marketed in Singapore contain NDMA above the acceptable level. Please refer to the letter for details.
Only abstracts of the Dear Healthcare Professional Letters (DHCPL) are provided on this website. Details of these letters can be found in the MOH Alert System, which is accessible via the Health Professionals Portal (HPP), a one-stop portal for all healthcare professionals in Singapore. Dentists, medical doctors and pharmacists may access HPP at https://hpp.moh.gov.sg and follow the procedures below to access the MOH Alert system.
Step 1: Select your profession under ‘For Healthcare Professionals’.
Step 2: Click on ‘Useful links’.
Step 3: Click on ‘MOH Alert’ and log in via Singpass.
Step 4: Click on ‘Drug Alerts’ or ‘Med Device Alerts’ to view the DHCPLs.
